stockrow
Saturday 7 November 2026
Export BCAX’s income statement to Excel — free account
Bicara Therapeutics Inc.
BCAX Healthcare Biotechnology
- EPS
- −64.0%
- Free cash flow
- −73.0%
Quarter to June 2026, against a year earlier
8.61
0.42
+5.13%
Follow BCAX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 49 | 49 | 49 | 0.0% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | (52) | (68) | (138) | (185) | +62.8% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | — | (52) | (68) | (138) | (185) | +62.9% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | (89.61) | (4.05) | (2.52) | (3.10) | (83.2%) | ||||||
| Cash flow | — | — | — | — | — | — | — | (78.66) | (4.45) | (1.95) | (1.99) | (84.2%) | ||||||
| Capex | — | — | — | — | — | — | — | (1.01) | 0.00 | (0.01) | (0.01) | (92.9%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | (79.67) | (4.45) | (1.96) | (1.99) | (84.3%) | ||||||
| Book value | — | — | — | — | — | — | — | (256.45) | 29.27 | 7.34 | 6.90 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | — | 1 | 17 | 55 | 59 | +870.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (46) | (75) | (107) | (135) | +53.0% | |||||
| Capex | — | — | — | — | — | — | — | (1) | 0 | 0 | 0 | (30.9%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | (46) | (75) | (107) | (135) | +52.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 216 | 485 | 393 | 460 | +34.9% | |||||
| Net debt | — | — | — | — | — | — | — | (230) | (490) | (415) | (497) | +34.2% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | (149) | 492 | 401 | 469 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (18.28) | (29.32) | (38.38) | (29.3) pt | |||||
| ROIC | — | — | — | — | — | — | — | 0.00 | (2,379.53) | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | — | 0.00 | (39.63) | (30.88) | (41.01) | (30.9) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 32 | 55 | 103 | — | +79.4% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Bicara Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ANL Adlai Nortye Ltd. Sponsored ADR | $568.5M | — | — | — | — | +46.03% (above 0%: growing) | — | — | Compare |
| ACRS Aclaris Therapeutics, Inc. | $559.5M | — (loss-making) | — (loss-making) | −55.11% (below 0%: shrinking) | n/m | −119.93% (below 0%: shrinking) | 0.00% | (1,441.19%) | Compare |
| IAM Iambic Therapeutics, Inc. | $551.7M | — | — | — | — | — | — | — | Compare |
| BCAX Bicara Therapeutics Inc. | $542.0M | — (loss-making) | — | — | n/m | −72.95% (below 0%: shrinking) | — | 0.00% | |
| VALN Valneva SE Sponsored ADR | $536.5M | 59.3× | 19.4× | −17.29% (below 0%: shrinking) | n/m | −56.05% (below 0%: shrinking) | 15.29% | (76.67%) | Compare |
| CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR | $524.8M | — (loss-making) | — (loss-making) | −7.53% (below 0%: shrinking) | n/m | −31.52% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ENTX Entera Bio Ltd. | $520.0M | — (loss-making) | — (loss-making) | +200.00% (above 0%: growing) | n/m | −108.86% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| FTH Faeth Therapeutics, Inc. | $514.8M | — (loss-making) | — | — | n/m | −262.66% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NGNE Neurogene Inc. | $513.3M | — (loss-making) | — (loss-making) | — | n/m | −22.97% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| Median of peers | $530.7M | — | — | −12.41% | — | −56.05% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 27 April 2026
Ownership
Directors and executive officers, together
13.80%
Entities affiliated with RA Capital Management, L.P.
11.10%
T. Rowe Price Investment Management, Inc.
10.10%
Kiran Mazumdar-Shaw
9.70%
Entities affiliated with Biocon Ltd
8.40%
Entities affiliated with Invus Public Equities, L.P.
8.00%
Vestal Point Capital, LP
5.40%
FMR LLC
5.10%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement